227 related articles for article (PubMed ID: 16327837)
1. The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases.
Vermeire S; Van Assche G; Rutgeerts P
Nat Clin Pract Gastroenterol Hepatol; 2005 Dec; 2(12):580-6. PubMed ID: 16327837
[TBL] [Abstract][Full Text] [Related]
2. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
4. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease.
Karadag F; Kirdar S; Karul AB; Ceylan E
Eur J Intern Med; 2008 Mar; 19(2):104-8. PubMed ID: 18249305
[TBL] [Abstract][Full Text] [Related]
5. Long pentraxin 3: a marker of inflammation in untreated psoriatic patients.
Bevelacqua V; Libra M; Mazzarino MC; Gangemi P; Nicotra G; Curatolo S; Massimino D; Plumari A; Merito P; Valente G; Stivala F; La Greca S; Malaponte G
Int J Mol Med; 2006 Sep; 18(3):415-23. PubMed ID: 16865225
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
[TBL] [Abstract][Full Text] [Related]
7. [C-reactive protein potential risk factor for cardiovascular disease].
Tornvall P; Pernow J; Hansson LO
Lakartidningen; 2003 Aug; 100(35):2691-3. PubMed ID: 14531129
[TBL] [Abstract][Full Text] [Related]
8. Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival.
Snaedal S; Heimbürger O; Qureshi AR; Danielsson A; Wikström B; Fellström B; Fehrman-Ekholm I; Carrero JJ; Alvestrand A; Stenvinkel P; Bárány P
Am J Kidney Dis; 2009 Jun; 53(6):1024-33. PubMed ID: 19394732
[TBL] [Abstract][Full Text] [Related]
9. Elevated C-reactive protein levels are not a feature of uncomplicated radiation-induced bowel injury.
Khalid U; Norman AR; Andreyev HJ
Eur J Cancer Care (Engl); 2007 Jul; 16(4):346-50. PubMed ID: 17587359
[TBL] [Abstract][Full Text] [Related]
10. [Is C-reactive protein a marker of inflammation?].
Dupuy AM; Terrier N; Sénécal L; Morena M; Leray H; Canaud B; Cristol JP
Nephrologie; 2003; 24(7):337-41. PubMed ID: 14650743
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease.
Chamouard P; Richert Z; Meyer N; Rahmi G; Baumann R
Clin Gastroenterol Hepatol; 2006 Jul; 4(7):882-7. PubMed ID: 16630759
[TBL] [Abstract][Full Text] [Related]
12. C-reactive protein (CRP) as tumor marker in pediatric and adolescent patients with Hodgkin disease.
Wieland A; Kerbl R; Berghold A; Schwinger W; Mann G; Urban C
Med Pediatr Oncol; 2003 Jul; 41(1):21-5. PubMed ID: 12764738
[TBL] [Abstract][Full Text] [Related]
13. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
Nordestgaard BG; Zacho J
Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):521-4. PubMed ID: 19695857
[TBL] [Abstract][Full Text] [Related]
14. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study.
Siemes C; Visser LE; Coebergh JW; Splinter TA; Witteman JC; Uitterlinden AG; Hofman A; Pols HA; Stricker BH
J Clin Oncol; 2006 Nov; 24(33):5216-22. PubMed ID: 17114654
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (recurrence and inflammation in the acute coronary syndromes) study.
Bogaty P; Boyer L; Simard S; Dauwe F; Dupuis R; Verret B; Huynh T; Bertrand F; Dagenais GR; Brophy JM
J Am Coll Cardiol; 2008 Jun; 51(24):2339-46. PubMed ID: 18549920
[TBL] [Abstract][Full Text] [Related]
16. [C-reactive protein and atherothrombosis--a prognostic factor or a risk factor?].
Yosef-Levi IM; Grad E; Danenberg HD
Harefuah; 2007 Dec; 146(12):970-4, 996. PubMed ID: 18254451
[TBL] [Abstract][Full Text] [Related]
17. Persistent activation of nuclear factor kappa-B signaling pathway in patients with unstable angina and elevated levels of C-reactive protein evidence for a direct proinflammatory effect of azide and lipopolysaccharide-free C-reactive protein on human monocytes via nuclear factor kappa-B activation.
Liuzzo G; Santamaria M; Biasucci LM; Narducci M; Colafrancesco V; Porto A; Brugaletta S; Pinnelli M; Rizzello V; Maseri A; Crea F
J Am Coll Cardiol; 2007 Jan; 49(2):185-94. PubMed ID: 17222729
[TBL] [Abstract][Full Text] [Related]
18. C-reactive protein. Should it be considered a coronary risk factor?
Aronow WS
Geriatrics; 2003 May; 58(5):19-22, 25. PubMed ID: 12756677
[TBL] [Abstract][Full Text] [Related]
19. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
[TBL] [Abstract][Full Text] [Related]
20. Biological markers in inflammatory rheumatic diseases.
Hilliquin P
Cell Mol Biol (Noisy-le-grand); 1995 Dec; 41(8):993-1006. PubMed ID: 8747080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
